Bacteremia 

  • Author: Nicholas John Bennett, MB, BCh, PhD; Chief Editor: Russell W Steele, MD   more...
 
Updated: Mar 18, 2010
 

Background

Bacteremia is the presence of viable bacteria in the circulating blood.[1] This may or may not have any clinical significance because harmless, transient bacteremia may occur following dental work or other minor medical procedures; however, this bacteremia is generally clinically benign and self-resolving in children who do not have an underlying illness or immune deficiency or a turbulent cardiac blood flow. The concern with occult bacteremia is that it could progress to a more severe local or systemic infection if left untreated. Most episodes of occult bacteremia spontaneously resolve, and serious sequelae are increasingly uncommon. However, serious bacterial infections occur, including pneumonia, septic arthritis, osteomyelitis, cellulitis, meningitis, and sepsis, possibly resulting in death.[2, 3]

With the development and widespread use of effective vaccines to the common serious bacterial infections of infancy (Haemophilus influenzae type B and Streptococcus pneumoniae), the rate of infectious caused by these pathogens has dramatically declined. Many of the studies in children with occult bacteremia were done prior to the introduction of one or both of these vaccines and, as such, may overestimate the likelihood of occult bacteremia.

Patients with occult bacteremia do not have clinical evidence other than fever (a systemic response to infection).[4] First described in the 1960s in young febrile children with unsuspected pneumococcal infection, bacteremia is defined as the presence of bacteria in the bloodstream of a febrile child who was previously healthy; the child does not clinically appear to be ill and has no apparent focus of infection.[5, 6] Occult bacteremia has been defined as bacteremia not associated with clinical evidence of sepsis (shock or purpura) or toxic appearance, underlying significant chronic medical conditions, or clear foci of infection (other than acute otitis media) upon examination in a patient who is discharged and sent home after an outpatient evaluation.[2]

Often, the only manifestation of occult bacteremia is fever or a minor infection (eg, otitis media, upper respiratory tract infection).[4] Therefore, in a busy clinic or emergency department, infants and young children with occult bacteremia are difficult to distinguish from others in the waiting-room.

Fever is common in pediatric patients. Children average 4-6 fevers by age 2 years.[7] Fever also prompts many visits to the pediatric clinic and emergency department. Approximately 8-25% of doctor's visits by children younger than 3 years are for fever;[4, 7, 8, 9] 65% of children younger than 3 years visit a physician for acute febrile illness.[8, 10]

Fever is less common in infants younger than 3 months than in those aged 3 months to 3 years. Young infants may not mount a fever response and may also be hypothermic in response to illness or stress.[7] Approximately 1% of infants younger than 2 months present with fever, and fever is twice as common in infants aged 1-2 months as it is in newborns younger than 1 month.[7]

Of all pediatric patients presenting for evaluation of fever, 20% have fever for which the source of infection is undetermined after a history and physical examination.[9] Of all infants and young children who present to the hospital for any reason, 1.6% appear nontoxic, were previously healthy, are older than 3 months, and have a fever without a source (FWS).[9]

Bacteremia may also occur in children with focal infections or in children who have sepsis (ie, clinical evidence other than fever of a systemic response to infection). Children with sepsis generally appear ill, have an increased heart rate or respiratory rate and may have a change in temperature (typically fever, although hypothermia is often seen in very young infants and newborns). Severe sepsis results in hypotension, hypoperfusion, or organ dysfunction. Septic shock occurs in children who do not respond to adequate volume resuscitation or require vasopressors or inotropes. Although bacteria may be present in the bloodstream of children with focal infections, sepsis, severe sepsis, or septic shock, the focus of this article is occult bacteremia.

Next

Pathophysiology

Much of the pathophysiology of occult bacteremia is not fully understood. The presumed mechanism begins with bacterial colonization of the respiratory passages or other mucosal surface; bacteria may egress into the bloodstream of some children because of host-specific and organism-specific factors. Once viable bacteria have gained access to the bloodstream, they may be spontaneously cleared, they may establish a focal infection, or the infection may progress to septicemia; the possible sequelae of septicemia include shock, disseminated intravascular coagulation, multiple organ failure, and death.[4, 11]

Often, fever is the only presenting sign in patients with occult bacteremia and is defined as increased temperature caused by resetting the thermoregulatory center in the hypothalamus by action of cytokines.[7] The cytokines may be produced in response to viral or bacterial pathogens or by immune complexes. An increased temperature does not always represent a fever. Hyperthermia may also be due to increased heat production as occurs in exercise or decreased heat loss as occurs in overbundling, neither of which involves resetting of the hypothalamic thermostat.

A child's immune system helps determine which bacteria gain initial access to the bloodstream, whether bacteremia spontaneously resolves or progresses to serious bacterial illness, and whether cytokines are produced to mount a fever response. The risk of life-threatening bacterial disease is greatest in young infants when their immune system is least mature; they have poor immunoglobulin G (IgG) antibody response to encapsulated bacteria and decreased opsonin activity, macrophage function, and neutrophil activity.[12, 13]

Clearly, some children are more susceptible to bacterial infection, which may initially be uncomplicated bacteremia but could rapidly lead to more serious complications. Immunosuppression due to neoplastic disease or its treatment or defects in antibody responses or neutrophil responses predispose certain children to invasive infection. Bacteremia should be considered, with a low threshold for evaluation and treatment, in patients with impaired immunity or invasive medical devices such as indwelling central venous lines.

The pathogens implicated in occult bacteremia change in response to vaccination against the common pathogenic strains. These changes govern the choices for empiric therapy of suspected bacteremia.

Previous
Next

Epidemiology

Frequency

United States

The risk of bacteremia has been studied by categorizing infants and young children based on age, appearance, temperature, laboratory criteria, numerous low-risk criteria based on a combination of these factors, and past medical history. These studies are part of an ongoing attempt to decide which children require evaluation and treatment and which children can be safely observed without intervention.

Numerous investigators have loosely and specifically defined the terms toxic and lethargic (see Physical). A child who is toxic or lethargic is generally described as making poor eye contact; having poor interactions with parents and the environment; and showing signs on global assessment of poor perfusion, hypoventilation or hyperventilation, or cyanosis.[8]

In children younger than 3 months, the risk of bacteremia is 1.2-2% in infants who are not toxic and 10-11% in infants who are toxic.[8, 14] In children aged 3-36 months who are toxic, the risk of bacteremia or serious bacterial infection ranges from 10-90%, depending on criteria.[8, 10]

Most studies designed to determine the relationship between temperature and risk of occult bacteremia define fever as a temperature of at least 38°C (100.4°F) in infants younger than 3 months and at least 39°C (102.2°F) in children aged 3-36 months. Because these studies were designed to predict occult bacteremia, they include children who have only FWS, which is defined as an acute febrile illness in which the etiology is not apparent after history is obtained and a careful physical examination is performed.[10]

Numerous studies published in the early 1990s found that 2-15% of febrile infants younger than 3 months had bacteremia.[12, 15, 13, 16] These studies also determined that the risk of occult bacteremia in children aged 3-36 months with FWS was 2.5-11%.[4, 8, 9, 17, 18] According to studies performed after the introduction of the conjugate Haemophilus influenzae type b (Hib) vaccine, the risk of occult bacteremia was 1.5-2.3% in children aged 3-36 months with FWS.[19, 20, 21]

Clinical trials and postlicensure studies suggest that the 7-valent conjugate pneumococcal vaccine is 90% effective in preventing invasive disease caused by Streptococcus pneumoniae. Widespread use has significantly decreased the overall risk of occult bacteremia, especially with regards to vaccine-specific strains of streptococcus.[9, 22, 23]

The appearance of the nonvaccine pneumococcus strain 19A, which has been responsible for some particularly invasive (and drug-resistant) infections, is a concern. This is discussed in more detail below.

International

According to the World Health Organization, at least 6 million children die each year of pneumococcal infections (eg, pneumonia, meningitis, bacteremia); most of these fatalities occur in developing countries.[24]

Mortality/Morbidity

The natural history, morbidity, and mortality associated with occult bacteremia alone are not clearly understood. In prospective studies of occult bacteremia, although many children were initially observed untreated, all were given antibiotics once blood culture findings became positive for known bacterial pathogens.[25] The widespread adoption of vaccines to the most common childhood bacteria pathogens (Hinfluenzae and S pneumoniae) have further complicated assessment because contemporary data are not directly comparable to historical studies.

In studies performed before the introduction of the Hib conjugate vaccine, children with untreated bacteremia had an 18-21% risk of developing persistent bacteremia and a 2-15% risk of developing important focal infections such as meningitis.[4, 8, 10, 26]

Because widespread use of the Hib vaccine has virtually eliminated invasive Hib disease in the developed world, recent reviews, analyses, and studies have focused on invasive S pneumoniae disease.[27] Children with occult pneumococcal bacteremia have a 6-17% risk of persistent bacteremia, a 2-5.8% risk of meningitis, and a 6-10% risk of other focal complications.[4, 2, 8, 28, 10, 21]

Of all focal infections that develop because of pneumococcal bacteremia, pneumococcal meningitis carries the highest risk for significant morbidity and mortality, including a 25-30% risk of neurologic sequelae such as deafness, mental retardation, seizures, and paralysis.[25, 9] The mortality rate of pneumococcal meningitis is 6.3-15%, and the overall mortality rate of pneumococcal bacteremia is 0.8%.[25, 9, 23]

Neisseria meningitidis also causes bacteremia in infants and young children. Although the prevalence of meningococcal bacteremia is much lower than that of pneumococcal disease (see Causes), the morbidity and mortality rates are much greater. Children with meningococcal bacteremia have a 42-50% risk of developing meningitis; a 50% risk of developing serious bacterial infection such as septic shock, pneumonia, and neurologic changes; a 3% risk of developing extremity necrosis; and an overall mortality rate of 4%.[4, 25, 9]

When untreated, Salmonella bacteremia carries a 50% risk of persistent bacteremia and can cause meningitis, sepsis, and death in infants younger than 3 months or in persons who are debilitated or immunocompromised.[2] However, in previously healthy children aged 3-36 months, the risk of meningitis or serious bacterial infection following Salmonella bacteremia is low.[4]

Race

Studies of the prevalence of bacteremia in children in diverse settings have identified no racial, geographic, or socioeconomic predisposition.[4, 6, 11, 29] However, antibiotic resistance patterns vary in different geographic regions, which may affect the treatment of children with bacteremia.

Sex

No sex-based difference in the prevalence or course of bacteremia is known.[11]

Age

Studies of occult bacteremia focus on children younger than 3 years. Some studies show that age does not affect the risk of developing occult bacteremia,[11] whereas other analyses have found that variations in age-based risk depend on the infecting organism.

Pneumococcal bacteremia is observed in children of all ages; however, children aged 6 months to 2 years are at an increased risk.[6, 2, 20] The prevalence of pneumococcal meningitis peaks in infants aged 3-5 months. Meningococcal bacteremia occurs most frequently in infants aged 3-12 months; the highest risk of meningococcal meningitis is in infants aged 3-5 months.[2, 11] The risk of Salmonella bacteremia is greatest in infants younger than 1 year, especially in those younger than 2 months.[2]

A seasonal variation in febrile children presenting for evaluation is recognized. The peak is from late fall to early spring in children of all ages and is likely because of respiratory and GI viral infections. Another peak occurs during the summer in infants younger than 3 months and is likely due to enteroviral infections and thermoregulation during hot weather.[7] However, most studies do not specifically address seasonal variation associated with bacteremia.

Previous
 
 
Contributor Information and Disclosures
Author

Nicholas John Bennett, MB, BCh, PhD  Fellow in Pediatric Infectious Disease, Department of Pediatrics, State University of New York Upstate Medical University

Nicholas John Bennett, MB, BCh, PhD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Pediatrics

Disclosure: Nothing to disclose.

Coauthor(s)

Joseph Domachowske, MD  Professor of Pediatrics, Microbiology and Immunology, Department of Pediatrics, Division of Infectious Diseases, State University of New York Upstate Medical University

Joseph Domachowske, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Brian J Holland, MD  Assistant Professor of Pediatrics, Pediatric Cardiology, University of Louisville School of Medicine

Brian J Holland, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, and American College of Cardiology

Disclosure: Nothing to disclose.

Specialty Editor Board

Itzhak Brook, MD, MSc  Professor, Department of Pediatrics, Georgetown University School of Medicine

Itzhak Brook, MD, MSc is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians-American Society of Internal Medicine, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, Armed Forces Infectious Diseases Society, Association of Military Surgeons of the US, Infectious Diseases Society of America, International Immunocompromised Host Society, International Society for Infectious Diseases, Medical Society of the District of Columbia, New York Academy of Sciences, Pediatric Infectious Diseases Society, Society for Ear, Nose and Throat Advances in Children, Society for Experimental Biology and Medicine, Society for Pediatric Research, Southern Medical Association, and Surgical Infection Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Mark R Schleiss, MD  American Legion Chair of Pediatrics, Professor of Pediatrics, Division Director, Division of Infectious Diseases and Immunology, Department of Pediatrics, University of Minnesota Medical School

Mark R Schleiss, MD is a member of the following medical societies: American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Robert W Tolan Jr, MD  Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine

Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility

Disclosure: GlaxoSmithKline Honoraria Speaking and teaching; MedImmune Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; Sanofi Pasteur Honoraria Speaking and teaching; Baxter Healthcare Honoraria Speaking and teaching; Novartis Honoraria Speaking and teaching

Chief Editor

Russell W Steele, MD  Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

References
  1. Spraycar M, ed. Stedman's Medical Dictionary. 26th ed. Baltimore, Md: Lippincott Williams & Wilkins; 1995.

  2. Kuppermann N. Occult bacteremia in young febrile children. Pediatr Clin North Am. Dec 1999;46(6):1073-109. [Medline].

  3. [Guideline] Kramer MS, Shapiro ED. Management of the young febrile child: a commentary on recent practice guidelines. Pediatrics. Jul 1997;100(1):128-34. [Medline].

  4. Harper MB, Fleisher GR. Occult bacteremia in the 3-month-old to 3-year-old age group. Pediatr Ann. Aug 1993;22(8):484, 487-93. [Medline].

  5. Lorin MI. Introduction and overview. Semin Pediatr Infect Dis. 1993;4:2-3.

  6. Swindell SL, Chetham MM. Occult bacteremia. Fever without localizing signs: the problem of occult bacteremia. Semin Pediatr Infect Dis. 1993;4:24-29.

  7. McCarthy PL. Fever. Pediatr Rev. Dec 1998;19(12):401-7; quiz 408. [Medline].

  8. [Guideline] Baraff LJ, Bass JW, Fleisher GR, et al. Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research. Ann Emerg Med. Jul 1993;22(7):1198-210. [Medline].

  9. Baraff LJ. Management of fever without source in infants and children. Ann Emerg Med. Dec 2000;36(6):602-14. [Medline].

  10. Baraff LJ. Management of infants and children 3 to 36 months of age with fever without source. Pediatr Ann. Aug 1993;22(8):497-8, 501-4. [Medline].

  11. Bass JW, Steele RW, Wittler RR, et al. Antimicrobial treatment of occult bacteremia: a multicenter cooperative study. Pediatr Infect Dis J. Jun 1993;12(6):466-73. [Medline].

  12. Baker MD. Evaluation and management of infants with fever. Pediatr Clin North Am. Dec 1999;46(6):1061-72. [Medline].

  13. Jaskiewicz JA, McCarthy CA. Evaluation and management of the febrile infant 60 days of age or younger. Pediatr Ann. Aug 1993;22(8):477-80, 482-3. [Medline].

  14. Baraff LJ, Oslund SA, Schriger DL, et al. Probability of bacterial infections in febrile infants less than three months of age: a meta-analysis. Pediatr Infect Dis J. Apr 1992;11(4):257-64. [Medline].

  15. Kadish HA, Loveridge B, Tobey J, et al. Applying outpatient protocols in febrile infants 1-28 days of age: can the threshold be lowered?. Clin Pediatr (Phila). Feb 2000;39(2):81-8. [Medline].

  16. Baskin MN. The prevalence of serious bacterial infections by age in febrile infants during the first 3 months of life. Pediatr Ann. Aug 1993;22(8):462-6. [Medline].

  17. Baraff LJ, Oslund S, Prather M. Effect of antibiotic therapy and etiologic microorganism on the risk of bacterial meningitis in children with occult bacteremia. Pediatrics. Jul 1993;92(1):140-3. [Medline].

  18. Jones RG, Bass JW. Febrile children with no focus of infection: a survey of their management by primary care physicians. Pediatr Infect Dis J. Mar 1993;12(3):179-83. [Medline].

  19. Alpern ER, Alessandrini EA, McGowan KL, et al. Serotype prevalence of occult pneumococcal bacteremia. Pediatrics. Aug 2001;108(2):E23. [Medline].

  20. Lee GM, Harper MB. Risk of bacteremia for febrile young children in the post-Haemophilus influenzae type b era. Arch Pediatr Adolesc Med. Jul 1998;152(7):624-8. [Medline].

  21. Lee GM, Fleisher GR, Harper MB. Management of febrile children in the age of the conjugate pneumococcal vaccine: a cost-effectiveness analysis. Pediatrics. Oct 2001;108(4):835-44. [Medline].

  22. Black SB, Shinefield HR, Hansen J, et al. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. Dec 2001;20(12):1105-7. [Medline].

  23. Kaplan SL, Mason EO Jr, Wald E, et al. Six year multicenter surveillance of invasive pneumococcal infections in children. Pediatr Infect Dis J. Feb 2002;21(2):141-7. [Medline].

  24. Giebink GS. The prevention of pneumococcal disease in children. N Engl J Med. Oct 18 2001;345(16):1177-83. [Medline].

  25. Kupperman N, Malley R, Inkelis SH, et al. Clinical and hematologic features do not reliably identify children with unsuspected meningococcal disease. Pediatrics. 1999;103:E20.

  26. Harper MB, Bachur R, Fleisher GR. Effect of antibiotic therapy on the outcome of outpatients with unsuspected bacteremia. Pediatr Infect Dis J. Sep 1995;14(9):760-7. [Medline].

  27. Chancey RJ, Jhaveri R. Fever without localizing signs in children: a review in the post-Hib and postpneumococcal era. Minerva Pediatr. Oct 2009;61(5):489-501. [Medline].

  28. Bauchner H, Pelton SI. Management of the young febrile child: a continuing controversy. Pediatrics. Jul 1997;100(1):137-8. [Medline].

  29. Fleisher GR, Rosenberg N, Vinci R, et al. Intramuscular versus oral antibiotic therapy for the prevention of meningitis and other bacterial sequelae in young, febrile children at risk for occult bacteremia. J Pediatr. Apr 1994;124(4):504-12. [Medline].

  30. Strait RT, Kelly KJ, Kurup VP. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 levels in febrile, young children with and without occult bacteremia. Pediatrics. Dec 1999;104(6):1321-6. [Medline].

  31. Dirnberger DR. Outpatient management of infants 28-60 days of age with fever without a source in a military setting. AAP Uniformed Services Section. 1996.

  32. Zuckerbraun NS, Zomorrodi A, Pitetti RD. Occurrence of serious bacterial infection in infants aged 60 days or younger with an apparent life-threatening event. Pediatr Emerg Care. Jan 2009;25(1):19-25. [Medline].

  33. Levine OS, Farley M, Harrison LH, et al. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics. Mar 1999;103(3):E28. [Medline].

  34. Bass JW, Wittler RR, Weisse ME. Social smile and occult bacteremia. Pediatr Infect Dis J. Jun 1996;15(6):541. [Medline].

  35. Bonadio WA. Defining fever and other aspects of body temperature in infants and children. Pediatr Ann. Aug 1993;22(8):467-8, 470-3. [Medline].

  36. [Guideline] Baraff LJ, Schriger DL, Bass JW, et al. Management of the young febrile child. Commentary on practice guidelines. Pediatrics. Jul 1997;100(1):134-6. [Medline].

  37. Mandl KD, Stack AM, Fleisher GR. Incidence of bacteremia in infants and children with fever and petechiae. J Pediatr. Sep 1997;131(3):398-404. [Medline].

  38. Greenes DS, Harper MB. Low risk of bacteremia in febrile children with recognizable viral syndromes. Pediatr Infect Dis J. Mar 1999;18(3):258-61. [Medline].

  39. Bass JW, Vincent JM, Demers DM. Oral antibiotic therapy for suspected occult bacteremia. J Pediatr. Dec 1994;125(6 Pt 1):1015-6. [Medline].

  40. Hsu K, Pelton S, Karumuri S, et al. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J. Jan 2005;24(1):17-23. [Medline].

  41. Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. Jun 2004;23(6):485-9. [Medline].

  42. Black S, Shinefield H, Baxter R, et al. Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine. Apr 12 2006;24 Suppl 2:S2-79-80. [Medline].

  43. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. Apr 25 2007;297(16):1784-92. [Medline].

  44. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. Jun 2007;26(6):468-72. [Medline].

  45. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. Nov 1 2007;196(9):1346-54. [Medline].

  46. Fernandez Lopez A, Luaces Cubells C, Garcia Garcia JJ, et al. Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker. Pediatr Infect Dis J. Oct 2003;22(10):895-903. [Medline].

  47. Pulliam PN, Attia MW, Cronan KM. C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection. Pediatrics. Dec 2001;108(6):1275-9. [Medline].

  48. Lacour AG, Gervaix A, Zamora SA, et al. Procalcitonin, IL-6, IL-8, IL-1 receptor antagonist and C-reactive protein as identificators of serious bacterial infections in children with fever without localising signs. Eur J Pediatr. Feb 2001;160(2):95-100. [Medline].

  49. Isaacman DJ, Burke BL. Utility of the serum C-reactive protein for detection of occult bacterial infection in children. Arch Pediatr Adolesc Med. Sep 2002;156(9):905-9. [Medline].

  50. Wack RP, Demers DM, Bass JW. Immature neutrophils in the peripheral blood smear of children with viral infections. Pediatr Infect Dis J. Mar 1994;13(3):228-30. [Medline].

  51. Gendrel D, Raymond J, Coste J, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J. Oct 1999;18(10):875-81. [Medline].

  52. Jaye DL, Waites KB. Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J. Aug 1997;16(8):735-46; quiz 746-7. [Medline].

  53. Gendrel D, Bohuon C. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J. Aug 2000;19(8):679-87; quiz 688. [Medline].

  54. Mariscalco MM. Is plasma procalcitonin ready for prime time in the pediatric intensive care unit?. Pediatr Crit Care Med. Jan 2003;4(1):118-9. [Medline].

  55. Leclerc F, Cremer R, Noizet O. Procalcitonin as a diagnostic and prognostic biomarker of sepsis in critically ill children. Pediatr Crit Care Med. Apr 2003;4(2):264-6. [Medline].

  56. Gendrel D, Raymond J, Assicot M, et al. Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis. Jun 1997;24(6):1240-2. [Medline].

  57. Bachur RG, Harper MB. Predictive model for serious bacterial infections among infants younger than 3 months of age. Pediatrics. Aug 2001;108(2):311-6. [Medline].

  58. Herr SM, Wald ER, Pitetti RD, et al. Enhanced urinalysis improves identification of febrile infants ages 60 days and younger at low risk for serious bacterial illness. Pediatrics. Oct 2001;108(4):866-71. [Medline].

  59. Levine DA, Platt SL, Dayan PS, et al. Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. Pediatrics. Jun 2004;113(6):1728-34. [Medline].

  60. Krief WI, Levine DA, Platt SL, et al. Influenza virus infection and the risk of serious bacterial infections in young febrile infants. Pediatrics. Jul 2009;124(1):30-9. [Medline].

  61. Bachur R, Perry H, Harper MB. Occult pneumonias: empiric chest radiographs in febrile children with leukocytosis. Ann Emerg Med. Feb 1999;33(2):166-73. [Medline].

  62. Walson PD, Galletta G, Chomilo F, et al. Comparison of multidose ibuprofen and acetaminophen therapy in febrile children. Am J Dis Child. May 1992;146(5):626-32. [Medline].

  63. Avner JR, Crain EF, Shelov SP. The febrile infant less than 10 days of age in the emergency department. Semin Pediatr Infect Dis. 1993;4:18-23.

  64. Baker MD, Bell LM, Avner JR. Outpatient management without antibiotics of fever in selected infants. N Engl J Med. Nov 11 1993;329(20):1437-41. [Medline].

  65. Baskin MN, O'Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. J Pediatr. Jan 1992;120(1):22-7. [Medline].

  66. Dagan R, Powell KR, Hall CB, et al. Identification of infants unlikely to have serious bacterial infection although hospitalized for suspected sepsis. J Pediatr. Dec 1985;107(6):855-60. [Medline].

  67. Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J. Oct 1995;14(10):885-90. [Medline].

  68. Rothrock SG, Harper MB, Green SM, et al. Do oral antibiotics prevent meningitis and serious bacterial infections in children with Streptococcus pneumoniae occult bacteremia? A meta-analysis. Pediatrics. Mar 1997;99(3):438-44. [Medline].

  69. Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003.

  70. Nilsson P, Laurell MH. Carriage of penicillin-resistant Streptococcus pneumoniae by children in day-care centers during an intervention program in Malmo, Sweden. Pediatr Infect Dis J. Dec 2001;20(12):1144-9. [Medline].

  71. Arditi M, Mason EO Jr, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics. Nov 1998;102(5):1087-97. [Medline].

  72. Isaacman DJ, Kaminer K, Veligeti H, et al. Comparative practice patterns of emergency medicine physicians and pediatric emergency medicine physicians managing fever in young children. Pediatrics. Aug 2001;108(2):354-8. [Medline].

  73. Nigrovic LE, Malley R. Evaluation of the febrile child 3 to 36 months old in the era of pneumococcal conjugate vaccine: focus on occult bacteremia. Clinical Pediatric Emergency Medicine. 2004;5.

  74. Obaro SK, Adegbola RA, Banya WA, et al. Carriage of pneumococci after pneumococcal vaccination. Lancet. Jul 27 1996;348(9022):271-2. [Medline].

  75. Advistory Committee for Immunization Practices. Draft ACIP recommendations for PCV13 vaccination schedule. Available at http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-oct09/11-2-PCV13.pdf. Accessed 12/14/09.

  76. DeAngelis C, Joffe A, Wilson M, et al. Iatrogenic risks and financial costs of hospitalizing febrile infants. Am J Dis Child. Dec 1983;137(12):1146-9. [Medline].

Previous
Next
 
Application of low-risk criteria and approach for the febrile infant: A reasonable approach for treating febrile infants younger than 3 months who have a temperature of greater than 38°C.
Application of algorithms for children aged 3-36 months: A reasonable approach for treating infants and young children aged 3-36 months who have a temperature of at least 39.5°C.
Table 1. Age, Fever, and Bacterial Infection[35]
AgeTemperature, Degrees CelsiusRate of Bacterial Infection, %
Neonates < 1 mo38-38.95
39-39.97.5
≥ 4018
Infants aged 1-2 mo38-38.93
39-39.95
≥ 4026
Table 2. Children Aged 3-36 Months - Fever and Occult Bacteremia[2, 4, 6, 9, 36]
Temperature, Degrees CelsiusOccult Pneumococcal Bacteremia, %Positive Blood Culture, %Positive Blood Culture, %Occult Pneumococcal Bacteremia, %
≤ 39Very low1.61
39-39.41.21.65
39.5-39.72.52.85
39.8-39.92.52.85
40-40.23.23.7510-10.4
40.3-40.53.23.7510-10.4
40.5-40.94.43.81210-10.4
≥ 419.39.21210-10.4
Table 3. Causes of Occult Bacteremia in Neonates and Infants with a Temperature of 38°C or Higher[15, 16, 12, 13, 14]
AgeOrganism*Positive Blood Cultures, %
Neonates < 1 moGroup B Streptococcus73
Escherichia coli8
S pneumoniae3
Staphylococcus aureus3
Enterococcus species3
Enterobacter cloacae3
Infants aged 1-2 moGroup B Streptococcus31
E coli20
Salmonella species16
S pneumoniae10
H influenzae type b6
S aureus4
E cloacae4
* Also, less frequently (< 1%), Listeria species, Klebsiella species, group A Streptococcus, Staphylococcus epidermis, Streptococcus viridans, and N meningitidis
Table 4. Causes of Occult Bacteremia and Changes Over Time in Children Aged 3-36 Months with FWS[4, 2, 8, 11, 17, 26, 20]
Organism*1975-1993, %1993, %1993-1996, %1990 to present, %
S pneumoniae83-86939289
H influenzae type b5-13200
N meningitidis1-3
Salmonella species1-7
* Also, less frequently (< 1%), E coli, S aureus, Streptococcus pyogenes, group B Streptococcus, Moraxella species, Kingella species, Yersinia species, and Enterobacter species
Table 5. Studies Evaluating the Established WBC More Than 15 per HPF Screen for Occult Bacteremia in FWS
StudyCutoffNPV, %PPV, %
Kuppermann, 1999[2] WBC >15996
Lee, 2001[21] WBC >15995
Strait, 1999[30] WBC >15986
Table 6. Recent Studies Reevaluating WBC Count as a Screen in FWS
StudyScreening GoalCutoff, per HPFNPV, %PPV, %
Fernandez Lopez, 2003[46] Invasive bacterial infection*WBC >176969
Pulliam, 2001[47] Serious bacterial infectionWBC >158930
Lacour, 2001[48] Serious bacterial infectionWBC >158946
Isaacman, 2002[49] Occult bacterial infection§WBC >179530
* Culture-positive bacteremia/meningitis/sepsis/bone/joint infection; dimercaptosuccinic acid (DMSA)–positive pyelonephritis; lobar pneumonia; bacterial enteritis in infants younger than 3 months



Culture-positive bacteremia/meningitis/septic arthritis/urinary tract infection (UTI); focal infiltrate on chest radiograph



Culture-positive bacteremia/meningitis/osteomyelitis; DMSA-positive pyelonephritis; lobar pneumonia



§ Culture-positive bacteremia/UTI; lobar pneumonia



Table 7. ANC as a Screen for Occult Bacteremia[2, 30]
ANCSensitivity, %Specificity, %PPV, %NPV, %
10,0007678899.2
>7,20082747.599.4
Table 8. Studies Reevaluating CRP level as a Screen in FWS
StudyScreening GoalCutoffNPV, %PPV, %
Lopez, 2003[46] Invasive bacterial infection*2.88169
Pulliam, 2001[47] Serious bacterial infection598Not reported
Lacour, 2001[48] Serious bacterial infection49651
Gendrel, 1999[51] Invasive bacterial infection§49734
Isaacman, 2002[49] Occult bacterial infectionll4.49430
* Culture-positive bacteremia/meningitis/sepsis/bone/joint infection; DMSA-positive pyelonephritis; lobar pneumonia; bacterial enteritis in infants younger than 3 months



Culture-positive bacteremia/meningitis/septic arthritis/UTI; focal infiltrate on chest radiography



Culture-positive bacteremia/meningitis/osteomyelitis; DMSA-positive pyelonephritis; lobar pneumonia



§ Culture-positive bacteremia/sepsis/meningitis



ll Culture-positive bacteremia/UTI; lobar pneumonia



Table 9. Recent Studies Evaluating PCT level as a Screen in FWS
StudyScreening GoalCutoffNPV, %PPV, %
Lopez, 2003[46] Invasive bacterial infection*0.69091
Lacour, 2001[48] Serious bacterial infection19755
Gendrel, 1999[51] Invasive bacterial infection29952
* Culture-positive bacteremia/meningitis/sepsis/bone/joint infection; DMSA-positive pyelonephritis; lobar pneumonia; bacterial enteritis in infants younger than 3 months



Culture-positive bacteremia/meningitis/osteomyelitis; DMSA-positive pyelonephritis; lobar pneumonia



Culture-positive bacteremia/sepsis/meningitis



Table 10. Effect of Illness Duration - PCT level as a Screen in FWS[46]
Illness DurationScreening GoalOptimal CutoffNPV, %PPV, %
Any (< 12 h and >12 h)Invasive bacterial infection*0.69091
< 12 hInvasive bacterial infection*0.79097
*Culture-positive bacteremia/meningitis/sepsis/bone/joint infection; DMSA-positive pyelonephritis; lobar pneumonia; bacterial enteritis in infants younger than 3 months
Table 11. Low-Risk Criteria for Infants Younger than 3 Months[64, 65, 66, 8]
CriterionPhiladelphiaBostonRochesterAAP 1993
Age1-2 mo1-2 mo0-3 mo1-3 mo
Temperature38.2°C≥ 38°C≥ 38°C≥ 38°C
AppearanceAIOS* < 15WellAnyWell
HistoryImmuneNo antibiotics in the last 24 h;



No immunizations in the last 48 h



Previously healthyPreviously healthy
ExaminationNonfocalNonfocalNonfocalNonfocal
WBC count< 15,000/μL; band-to-neutrophil ratio



< 0.2



< 20,000/μL5-15,000/μL;



ABC < 1,000



5-15,000/μ L;



ABC < 1,000



Urine assessment< 10 WBCs per HPF;



Negative for bacteria



< 10 WBCs per HPF;



Leukocyte esterase negative



< 10 WBCs per HPF< 5 WBCs per HPF
CSF assessment< 8 WBCs per HPF;



Negative for bacteria



< 10 WBCs per HPF< 10-20 WBCs per HPF
Chest radiographyNo infiltrateWithin reference range, if obtainedWithin reference range, if obtained
Stool culture< 5 WBCs per HPF< 5 WBCs per HPF
* Acute illness observation score
Table 12. Occult Bacteremia - Relationship Between Outpatient Antibiotic Use and Complications[8, 10, 26, 11, 67]
ComplicationNo Antibiotic Therapy, %Oral Antibiotic Therapy, %Intramuscular/Intravenous Antibiotic Therapy, %
Persistent bacteremia18-213.8-50-5
New focal infection135-6.65-7.7
Meningitis9-104.5-8.20.3-1
Table 13. Pneumococcal Bacteremia - Relationship Between Outpatient Antibiotic Use and Complications[2, 8, 10, 18, 21, 28, 36, 68, 9]
ComplicationNo Antibiotic Therapy, %Any Antibiotic Therapy, %Oral Antibiotic Therapy, %Intramuscular/Intravenous Antibiotic Therapy, %
Persistent bacteremia7-171-1.52.5
Focal infection/SBI9.7-103.3-4
Meningitis2.7-60.4-10.4-1.50.4-1
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.